Ardea Biosciences News

President and CEO of ARDEA BIOSCIENCES, INC. Barry D Quart sells 25,000 shares of RDEA on 12/09/2009 at an average price of $14.48 a share.

The report also includes earnings and earnings per share, margin and return ratios, financial strength, growth ratios, dayA's sales outstanding, dayA's outstanding inventory, cash and short-term investments per share and total common shares outstanding.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Owens-Illinois , Gerdau , Western Digital , USG Corp , Ardea Biosciences and Monsanto and each have a high seasonal probability to go higher in the next 5 weeks.

ARDEA BIOSCIENCES, INC. filed Quarterly Report for the period ended 2009-09-30. IntraBiotics Pharmaceuticals Inc.

Oct 19, 2009 - Ardea Biosciences, Inc. today announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report for Tuesday, October 6th, 2009 and come to the following statistical conclusions.

Sep 30, 2009 - Ardea Biosciences, Inc. today announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology / Association of Rheumatology Health Professionals Annual Scientific Meeting in Philadelphia, ...

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

August 7, 2009 Ardea Biosciences, Inc. trading at $20.92 on a volume of 16,439 shares.

August 7, 2009 Ardea Biosciences, Inc. trading at $20.92 on a volume of 16,439 shares.

August 7, 2009 Ardea Biosciences, Inc. trading at $20.92 on a volume of 16,439 shares.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Aug 7, 2009 - Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus , today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2009.

August 7, 2009 Ardea Biosciences, Inc. trading at $20.92 on a volume of 16,439 shares.

Main Category: Gout Also Included In: Clinical Trials / Drug Trials Article Date: 22 Jul 2009 - 1:00 PDT printer friendly view / write opinions rate article Ardea Biosciences, Inc.

AUSTIN, Texas-- --LDR, a total spine solution company, announced today that it has begun to market its ROI-C cervical cage following 510 clearance from the United States Food and Drug - MOUNTAIN VIEW, Calif.-- --OfficeRecovery.com announces improved support for Microsoft SQL Server backups and logs in its data recovery software.